Abstract ; Background : Myeloma cells may secrete factors that affect the function of osteoblasts, osteoclasts, or both. Methods : We subjected purified plasma cells from the bone marrow of patients with newly diagnosed multiple myeloma and control subjects to oligonucleotide microarray profiling and biochemical and immunohistochemical analyses to identify molecular determinants of osteolytic lesions. Results : We studied 45 control subjects, 36 patients with multiple myeloma in whom focal lesio...
Plasma Cell Neoplasm, M Protein Type, Pathology ; MGUS, IgG kappa or lambda; or IgA kappa or lambda, <10% plasma cells in bone marrow ; Isolated plasmacytoma of bone, IgG kappa or lambda; or IgA kappa or gamma, Solitary lesion of bone; <10% plasma cells in marrow of uninvolved site ; Extramedullary plasmacytoma, IgG kappa or lambda; or IgA kappa or gamma, Solitary lesion of soft tissue; most commonly occurs in the nasopharynx, tonsils, or paranasal sinuses [ 3 ] ; Multiple myeloma, IgG kappa or lambda; or IgA kappa or gamma, Often, multiple lesions of bone
Diagnosing multiple myeloma usually begins with a visit to your family doctor. Your doctor will ask you about any symptoms you have and do a physical exam. Based on this information, your doctor may refer you to a specialist or order tests to check for multiple myeloma or other health problems. The process of diagnosis may seem long and frustrating. It’s normal to worry, but try to remember that other health conditions can cause similar symptoms as multiple myeloma. It’s important for the healthcare team to rule out other reasons for a heal ...
INTENDED USE Sigma-Aldrich Alkaline Phosphatase kits are intended for the histochemical semi-quantitative demonstration of alkaline phosphatase activity in leukocytes. Alkaline Phosphatase...
Abstract Introduction: Bone involvement in Multiple Myeloma results from increased osteoclast... to myeloma cells. The role of Alkaline Phosphatse (ALP) in this process and the diagnostic...
Abstract ; Background : Skeletal complications are a major clinical manifestation of multiple myeloma. These complications are caused by soluble factors that stimulate osteoclasts to resorb bone. Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bone resorption. Methods : Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addi...
Differential, Fracture Fixation, methods, Fractures, Spontaneous, diagnosis, etiology, therapy, Humans, Magnetic Resonance Imaging, Multiple Myeloma, complications, drug therapy, Treatment Outcome
Technique ; Numerous methods utilizing different substrates and reaction conditions have been applied to measurement of ALP activity. The heterogeneity of methods presents problems with comparing results from different laboratories and often compromises the current application of data previously reported in the literature. Recent methodologic changes have emphasized the need for standardization and optimization of the assay. Readily hydrolyzed, self-indicating substrates that permit continuous m...
US Pharm. 2008;33(4)(Oncology suppl):6-19. Etiology/Risk Factors · The exact cause of multiple myeloma is unknown. The major risk factor for development is exposure to ionizing radiation. This may take the form of chronic low-dose exposure through many diagnostic x-rays over time or a large, single exposure such as an atomic bomb or proximity to a compromised nuclear reactor.2 Exposure to pesticides and herbicides, including Agent Orange, may also increase the risk.2 There is also an increased...
Abstract Read online Introduction: Bone involvement in Multiple Myeloma results from... to myeloma cells. The role of Alkaline Phosphatse (ALP) in this process and the diagnostic...